NewsBenzingaMerck Signs Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Preclinical Oral KRAS G12D Inhibitor, For $400M Up Front Plus Payments; Company To Record Pre-Tax Charge Of $0.13 Per Share In Q3 Merck Signs Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Preclinical Oral KRAS G12D Inhibitor, For $400M Up Front Plus Payments; Company To Record Pre-Tax Charge Of $0.13 Per Share In Q3 Benzinga 2026.09.28 10:48 (GMT+0) Open on Benzinga Other news Signal restricts mobile screenshots as it confronts ‘existential threat’ of AI surveillance Why It’s Time to Buy the Pullback in Broadcom Stock A tale of two Nvidias These Are the Top 10 Largest IPOs Following Anthropic's Historic Market Debut Nvidia Has a New Problem, And It’s Not What You Think Tesla Begins FSD v15 Rollout to First-Wave Customers